386 related articles for article (PubMed ID: 36455990)
1. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
Ascierto PA; Schadendorf D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
[TBL] [Abstract][Full Text] [Related]
2. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
3. Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors.
Hooiveld-Noeken JS; Eggen AC; Rácz E; de Vries EGE; Reyners AKL; Jalving M
Crit Rev Oncol Hematol; 2022 Dec; 180():103855. PubMed ID: 36257534
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment of advanced cutaneous squamous-cell carcinoma.
Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
[TBL] [Abstract][Full Text] [Related]
6. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer.
Chen L; Aria AB; Silapunt S; Migden MR
Dermatol Surg; 2019 Jan; 45(1):1-16. PubMed ID: 30045105
[TBL] [Abstract][Full Text] [Related]
7. Update of cetuximab for non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?
Moujaess E; Merhy R; Kattan J; Sarkis AS; Tomb R
Immunotherapy; 2021 Oct; 13(15):1293-1304. PubMed ID: 34463126
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
Wessely A; Steeb T; Leiter U; Garbe C; Berking C; Heppt MV
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291277
[TBL] [Abstract][Full Text] [Related]
10. Non-Surgical Therapeutic Strategies for Non-Melanoma Skin Cancers.
Zeng Q; Chen C; Chen D; Zhang G; Wang X
Curr Treat Options Oncol; 2023 Dec; 24(12):1978-1993. PubMed ID: 38095778
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
Giri A; Bauman JR
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
[TBL] [Abstract][Full Text] [Related]
12. Treatment approaches of advanced cutaneous squamous cell carcinoma.
Peris K; Piccerillo A; Del Regno L; Di Stefani A
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():19-22. PubMed ID: 34855254
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes.
Shalhout SZ; Kaufman HL; Emerick KS; Miller DM
Clin Cancer Res; 2022 Jun; 28(11):2211-2220. PubMed ID: 35121622
[TBL] [Abstract][Full Text] [Related]
14. Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer.
Wilken R; Criscito M; Pavlick AC; Stevenson ML; Carucci JA
Facial Plast Surg; 2020 Apr; 36(2):200-210. PubMed ID: 32413929
[TBL] [Abstract][Full Text] [Related]
15. Surgery in the Era of Immunotherapy for Advanced Head and Neck Non-melanoma Skin Cancer.
Lin A; Schmalbach CE
Curr Oncol Rep; 2023 Jul; 25(7):735-742. PubMed ID: 37010785
[TBL] [Abstract][Full Text] [Related]
16. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
Jansen P; Lodde GC; Wetter A; Welt A; Stuschke M; Dührsen U; Stoffels I; Klode J; Livingstone E; Zimmer L; Roesch A; Hadaschik E; Griewank KG; Schadendorf D; Ugurel S
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():41-44. PubMed ID: 34855243
[TBL] [Abstract][Full Text] [Related]
18. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
In GK; Vaidya P; Filkins A; Hermel DJ; King KG; Ragab O; Tseng WW; Swanson M; Kokot N; Lang JE; Menendez L; DeClerck B; Kim G; Hu JC; Terando A; Jadvar H; Ricker C; Miller KA; Peng DH; Wysong A
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1803-1811. PubMed ID: 33210210
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer.
Aboul-Fettouh N; Kubicki SL; Chen L; Silapunt S; Migden MR
Dermatol Clin; 2023 Jan; 41(1):23-37. PubMed ID: 36410980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]